THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R.1437 (P.L. 117-229), Further Continuing Appropriations and Extensions Act. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as they relate to pandemic preparedness.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Health Issues HCR
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines. S. 3799, PREVENT Pandemics Act. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to public health preparedness and response.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Defense DEF
NDAA for FY 2023 - provisions related to biological and chemical defense and access to naloxone.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.